EcoDrugPlus

Estrogen Receptor Beta-1-Like

Ensembl ID : ENSAMXG00000036234
Gene Symbol: LOC103028984
3 Cross references
200 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSAMXG00000033809
Gene Symbol: ESRRGA
1 Cross references
201 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSAMXG00000033230
Gene Symbol: FDPS
1 Cross references
269 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSAMXG00000033139
Gene Symbol: FDFT1
3 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSAMXG00000005949
Gene Symbol: FNTA
3 Cross references
222 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSAMXG00000015547
Gene Symbol: FGFR1A
1 Cross references
209 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSAMXG00000003805
Gene Symbol: FGFR2
1 Cross references
221 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSAMXG00000012387
Gene Symbol: FGFR3
1 Cross references
194 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSAMXG00000014301
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSAMXG00000001322
Gene Symbol: FLT4
1 Cross references
197 Possible Orthologues:

Folate Receptor Gamma

Ensembl ID : ENSAMXG00000011581
Gene Symbol: LOC103026309
3 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSAMXG00000011613
Gene Symbol: FSHR
2 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).